The medication's effects on appetite suppression and significant weight loss can lead to reduced dietary intake and potential nutritional deficiencies
What we tried to do with the development of Oikos Fusion was really lean into the nutrition science to understand what nutrients people taking a GLP-1 drug would be most likely be deficient in due to their lower caloric or energy intake, and really understand from a nutrition perspective, how we could uniquely support them, she said
Various early studies, mostly in rodents, have shown promise in this area and future research is sure to lead to new discoveries, which will in turn trigger others
Semaglutide is recommended for people with obesity, BMI greater than 30 kg/m2 or BMI greater than 27 Kg/m2 with a weight-related condition like diabetes type II or high blood pressure or high cholesterol
Higher-dose weight loss7.2mg/wk The current adult Wegovy injection label permits 7.2 mg after at least four weeks at 2.4 mg when additional weight reduction is needed